Surgical Site Infection Control Market Report 2026

The surgical site infection control market size has grown steadily in recent years. It will grow from $4.96 billion in 2025 to $5.2 billion in 2026 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to increasing surgical procedure volumes, rising awareness of healthcare-associated infections, expansion of hospital infrastructure, wider availability of antiseptic and disinfectant products, strengthening of clinical hygiene standards.

The surgical site infection control market size is expected to see steady growth in the next few years. It will grow to $6.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing investments in infection control technologies, rising regulatory enforcement of infection prevention guidelines, expansion of digital hospital monitoring systems, growing focus on patient safety outcomes, increasing adoption of antimicrobial surgical solutions. Major trends in the forecast period include increasing adoption of comprehensive infection prevention protocols, rising use of advanced sterilization products, growing integration of digital ssi monitoring systems, expansion of disposable surgical consumables, enhanced focus on post-operative infection reduction.

The increasing number of surgical procedures is expected to drive the growth of the surgical site infection control market in the coming years. The rise in surgeries is fueled by technological advancements, an expanding elderly population, and a growing burden of chronic diseases. Surgical site infection control measures, including sterilization, antibiotic prophylaxis, and aseptic techniques, are critical for preventing infections, minimizing complications, and improving patient outcomes. For example, in September 2023, according to the National Library of Medicine, a US-based federal government agency, as of 2023 there were 7,733 robotic surgical systems installed worldwide, and more than 10 million robotic surgeries had been performed. Therefore, the rising number of surgical procedures is boosting demand for surgical site infection control solutions.

Key companies in the surgical site infection control market are concentrating on developing innovative infection prevention solutions to reduce surgical site infection rates, enhance patient safety, and improve postoperative outcomes in healthcare settings. Surgical site infection control encompasses strategies, products, and practices designed to prevent infections at surgical incision sites, thereby reducing complications and improving patient recovery. For instance, in November 2025, BD (Becton, Dickinson and Company), a US-based medical technology firm, launched BD Surgiphor in Europe. The device is intended to enhance surgical safety by minimizing contamination risks during procedures, supporting sterile practices, and lowering the incidence of surgical site infections. Through this launch, BD aims to strengthen its surgical safety portfolio, promote the adoption of advanced infection control solutions, and improve patient outcomes in European operating rooms.

In February 2023, Ansell Limited, an Australia-based manufacturing company, acquired a 50% stake in Careplus (M) Sdn Bhd for US$9 million. This acquisition aligns with Ansell’s goal of securing greater control over its supply chain and manufacturing operations. Careplus (M) Sdn Bhd is a Malaysia-based manufacturer specializing in surgical, latex, and nitrile powder-free gloves.

Major companies operating in the surgical site infection control market are Johnson and Johnson, Thermo Fisher Scientific Inc., 3M Company, Kimberly-Clark Corporation, Becton Dickinson and Company, Owens & Minor Inc., B. Braun Melsungen AG, Smith & Nephew plc, Hartmann Group, ConvaTec Inc., Ansell Limited, Mölnlycke Health Care, Halyard Health Inc., DeRoyal Industries Inc., Excelsior Medical LLC, Precept Medical Products Inc., Cantel Medical Corp, Medline Industries LP, Cardinal Health Inc., Terumo Corporation, Stryker Corporation, Philips Healthcare.

North America was the largest region in the surgical site infection control market in 2025. The regions covered in the surgical site infection control market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the surgical site infection control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the surgical site infection control market by increasing costs of imported disinfectants, medical nonwovens, surgical gloves, sterilization equipment, and monitoring systems. Hospitals and ambulatory surgical centers in North America and Europe are most affected due to reliance on imported infection control consumables, while Asia-Pacific faces cost pressure on export-driven production. These tariffs are increasing operational costs for healthcare providers. However, they are also driving domestic manufacturing of infection control products, regional supplier diversification, and long-term resilience in healthcare supply chains.

The surgical site infection control market research report is one of a series of new reports that provides surgical site infection control market statistics, including surgical site infection control industry global market size, regional shares, competitors with a surgical site infection control market share, detailed surgical site infection control market segments, market trends and opportunities, and any further data you may need to thrive in the surgical site infection control industry. This surgical site infection control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Surgical site infection (SSI) control involves a set of practices designed to prevent infections that develop at or near a surgical incision within 30 days of the procedure, or up to 90 days for certain surgeries. These practices include maintaining sterile conditions, proper hand hygiene, antibiotic prophylaxis, and post-operative wound care. Effective SSI control is critical for reducing patient morbidity, mortality, and healthcare costs.

The main product types for surgical site infection control include surgical scrubs, hair clippers, surgical drapes, surgical irrigation systems, skin preparation solutions, medical nonwovens, surgical gloves, manual reprocessor solutions, disinfectants, and others. Surgical scrubs are specialized garments worn by surgical staff to maintain cleanliness and minimize the spread of microorganisms during procedures. SSI can manifest as superficial incisional, deep incisional, or organ/space infections. These products are used in a variety of surgeries, including cesarean sections, gastric bypass, cataract surgery, dental restoration, and more, and serve end users such as hospitals, ambulatory surgical centers, and others.

The surgical site infection control market consists of sales of sterile surgical gloves and instruments, antiseptic skin preparation solutions, and post-operative dressings. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.